THE RELATION BETWEEN MODIFIED SYSTEMIC INFLAMMATION SCORE AND PROGNOSTIC MARKERS OF GASTROINTESTINAL STROMAL TUMORS

Abstract

Objective Gastrointestinal stromal tumours are tumours of mesenchymal origin that can be located along the gastrointestinal tract. In this study, the role of Modified systemic inflammation score in predicting the prognosis of these tumours was investigated. Material and Method 115 patients diagnosed with Gastrointestinal Stromal Tumor (GIST) who underwent surgery at Ankara City Hospital between June 1, 2019 and December 1, 2022 were examined. Tumor location, size, presence of rupture-bleeding-necrosis, Ki-67 level, mitotic index and preoperative albumin, lymphocyte and monocyte levels were evaluated. mSIS score was grouped as 0, 1 and 2. The relationship between mSIS and Ki- 67 index and the presence of rupture, necrosis and bleeding was investigated. Results Out of 115 patients, 68 (59 %) were male, 47 (41 %) were female, with an average age of 62.5 (± 12.67) years. Tumor locations: stomach (64.3 %), small intestine (26 %), colon (5.2 %), esophagus (1.8 %), pancreas (1.8 %), and ovary (0.9 %). Necrosis was in 25 (30.7 %), hemorrhage in 67 (58.7 %), rupture in 19 (16.8 %), and the mean Ki-67 level was 9.09 (± 10.64). 63 (54.8 %) patients had mSIS 0, 29 (25.2 %) had mSIS 1, and 23 (20 %) had mSIS 2. Statistical analysis found a significant correlation between mSIS and necrosis, but not with other parameters. Conclusion The mSIS score is a valuable score showing inflammation in the body and has been shown to be associated with the prognosis of many malignancies. In our study, the presence of necrosis in the tumour was found to be associated with the mSIS score. Although this result alone is not sufficient to predict the prognosis, it is thought to be an issue that may open the door to new studies.